Skin cancer has become one of the fastest-growing cancers worldwide, with tens of millions of new cases diagnosed each year. Yet the standard treatment for basal cell carcinoma (BCC), the most common form of skin cancer, remains surgical removal. Surgery is effective but costly, can leave scars, and often must be repeated for patients who develop multiple lesions. Growing demand for noninvasive alternatives has created opportunities for companies developing targeted, patient-friendly therapies. One such innovator is Medicus Pharma Ltd. (NASDAQ: MDCX).
MDCX is a clinical-stage biotechnology company advancing late-stage programs in oncology and urology. Its lead candidate, Skinject(TM), is in mid-Phase 2 development for BCC, while Teverelix TFA, a recently acquired asset, targets prostate conditions. Combined, these programs address markets estimated at $8 billion globally.
Transforming Skin Cancer Treatment with Skinject(TM)
Through its wholly owned subsidiary SkinJect Inc., Medicus is developing Skinject(TM), a dissolvable microneedle patch that delivers doxorubicin directly into tumor cells. The therapy aims to provide a non-surgical, localized treatment for BCC, reducing the need for cutting, scarring, and repeated interventions.
After a Phase 1 safety and tolerability trial (SKNJCT-001) completed in March 2021, in which all 13 participants tolerated treatment and six achieved complete tumor clearance, Medicus advanced Skinject(TM) to a multicenter Phase 2 program.
The SKNJCT-003 trial, launched in August 2024 across nine U.S. sites, reached over 75% enrollment of its 90-patient target by mid-2025. Interim March data showed more than 60% clinical clearance with no dose-limiting toxicities. Encouraged by results, Medicus expanded to European sites and plans to complete recruitment by the end of Q4 2025. An End-of-Phase 2 meeting with the FDA is scheduled for Q1 2026.
In September 2025, FDA Type C feedback confirmed Skinject(TM) may qualify for the 505(b)(2) regulatory pathway, a streamlined approval route leveraging existing safety data from approved drugs. This pathway could shorten timelines and reduce costs. “Establishing 505(b)(2) as a regulatory pathway is a game changer,” said CEO Dr. Raza Bokhari. “By leveraging existing doxorubicin data, we save costs and gain valuable time.” Medicus estimates Skinject(TM)’s market potential at roughly $2 billion.
Expanding Global Clinical Footprint
Medicus launched SKNJCT-004, a Phase 2 study in the UAE at six hospitals, including Cleveland Clinic Abu Dhabi and Sheikh Shakbout Medical City. The 36-patient study tests two Skinject(TM) doses versus placebo. Including international data is expected to strengthen global regulatory positioning.
The FDA also recommended formulation improvements, such as adding an adhesive layer and applicator system, to ensure consistency and usability. These steps are key toward potential commercialization around 2027.
Compassionate Use for Rare Skin Cancer Syndrome
In October 2025, Medicus partnered with the Gorlin Syndrome Alliance to establish a compassionate-use pathway for Skinject(TM) in patients with Gorlin Syndrome, a rare disorder affecting roughly 1 in 31,000 people worldwide. These patients may develop hundreds of BCC lesions over their lifetimes, often requiring repeated surgeries.
Through an Expanded Access IND program with the FDA, physician-supervised treatment will provide real-world data. “Patients with Gorlin Syndrome endure a lifelong burden of recurring skin cancers,” said Dr. Bokhari. “Our collaboration underscores our mission to bring targeted innovation where medical need is greatest.”
Strengthening the Pipeline with Teverelix TFA
In August 2025, Medicus acquired UK-based Antev Limited, adding Teverelix TFA, a next-generation GnRH antagonist with potential best-in-class cardiovascular safety. The deal, valued at $2.97 million in cash and 1.6 million MDCX shares plus up to $65 million in milestones, bolsters Medicus’s late-stage pipeline.
Teverelix is being evaluated in two FDA-cleared Phase 2b trials: preventing relapse in Acute Urinary Retention and treating Advanced Prostate Cancer in high-risk patients. Combined, these represent a $6 billion market opportunity. Unlike traditional GnRH agonists, Teverelix suppresses hormone production without an initial testosterone surge, potentially reducing cardiovascular side effects. Its six-week dosing interval could improve adherence. Following the acquisition, biotech veteran Patrick J. Mahaffy, former CEO of Clovis Oncology and Pharmion, joined Medicus’s board.
Financial Stability and Strategic Growth
To fund these programs, Medicus completed an $8 million non-dilutive debenture financing with Yorkville Advisors Global in October 2025. Net proceeds of $5.7 million will support Teverelix advancement. As of Q2 2025, cash and equivalents totaled $9.7 million, up from $4.0 million in Q1. R&D expenses were $1.4 million, with total operating expenses of $6.0 million, reflecting expanded global trials and acquisition costs.
Dr. Bokhari summarized: “The fundamentals of Medicus are extremely strong today. We are making great progress with Skinject(TM) while strategically advancing other high-value assets.”
Looking Ahead
With late-stage clinical programs advancing on multiple fronts, MCDX is positioning itself at the forefront of patient-centered innovation in oncology and urology. As Skinject(TM) progresses toward Phase 3 readiness and Teverelix TFA advances through key milestones, the company aims to deliver transformative, accessible therapies addressing significant global markets. Supported by strategic financing and an experienced leadership team, MCDX appears well prepared to drive long-term value and redefine standards of care in its target indications.